Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Activity of 4-HPR in superficial bladder caner using DNA flow cytometry as an intermediate endpoint (1992)
    New York, N.Y. : Wiley-Blackwell
    Journal of Cellular Biochemistry 50 (1992), S. 139-147 
    Details
    ISSN: 0730-2312
    Keywords: 4-HPR ; bladder cancer ; chemoprevention ; DNA flow cytometry ; intermediate endpoints ; retinoids ; Life and Medical Sciences ; Cell & Developmental Biology
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Biology , Chemistry and Pharmacology , Medicine
    Notes: The ability ofthesynthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) to affect the outcome of previously resected superficial bladder cancer was investigated in apilot study using DNA content flow cytometry and conventional cytology as intermediate endpoints. Twelve patients were treated with oral 4-HPR (200 mg daily) and compared with 17 non-randomized, untreated controls. The median interval between transurethral resection and 4-HPR administration was 5.5 months (rangs 0-36). The median follow-up period was 12 months (rang 3-31) in the4-HPR group and 9 months (range 2-22) in the control group. The proportion of patients with DNA aneuploid stemlines in bladder-washed cells decreased form 7/12 (58%) to5/11 (45%) in the 4-HPR group, but increased form 7/17 (41%) to 10/17(59%) in the control group. In patients with stable diploid profiles, mean (±SE) S-phase and G2-M-phase fractions decreased in the course of retinoid treatment from basal levels of 15.2±4.1% to 7.5±3.3% and 10.3±2.2% to 5.2 ±0.4%, respectively. The same parameters in the control group changes from basal levels of 14.6±3.4% to 12.4±2.7% and 9.8±1.6% to 12.6±1.6%, respectively. Positive or suspicious cytologic examinations were present in 3/12 (25%) treated cases prior to 4-HPR) administration and all subsequently reverted to normal. The same parameter in the control group increased from 4/17 (24%) to 6/17 (35%)during follow-up. Impaired adaptation to darekness was recorded in 4 patients, and transient dermatologic alterations were observed in one-third of the patients, requiring dose reduction in one case. Our preliminary data suggest that4-HPR may affect theDNA content and abnormal cytology in patients with previously resected superficial bladder cancer. © 1992 Wiley-Liss, Inc.
    Additional Material: 2 Ill.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1002/jcb.240501327
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Breast cancer chemoprevention: Studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints (1993)
    New York, N.Y. : Wiley-Blackwell
    Journal of Cellular Biochemistry 53 (1993), S. 226-233 
    Details
    ISSN: 0730-2312
    Keywords: Breast cancer ; chemoprevention ; EGF ; 4-HPR ; growth factors ; IGF-I ; retinoid ; retinol ; tamoxifen ; TGF-β ; Life and Medical Sciences ; Cell & Developmental Biology
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Biology , Chemistry and Pharmacology , Medicine
    Notes: Fenretinide (4-HPR), a synthetic derivative of retinoic acid, has proven effective at inhibiting in vitro breast cancer cell growth and preventing the progression of chemically induced mammary carcinoma in rodents. Our group has made a particular effort with regard to this molecule in clinical studies aimed at evaluating its pharmacology, toxicity, and efficacy in breast cancer prevention. We have demonstrated that 4-HPR blood levels remain constant during administration for as long as 5 years, that the drug accumulates in the human breast, and that it induces a significant decline of plasma insulin-like growth factor-I (IGF-I) levels. To date, 2,972 Stage I breast cancer patients have been randomized to evaluate the efficacy of a 5-year administration of 4-HPR to prevent new contralateral primary breast cancers. Compliance to protocol and treatment is high and tolerability of the drug is good; only 51 women out of 1,397 (3.6%) had to interrupt drug intake due to toxicity. The only potential limitation to the extensive use of 4-HPR is diminished dark adaptation, which occurs in about one-fourth of the patients and is dependent on the decline of plasma retinol below the threshold level of 100 ng/ml. Plasma levels of (4-methoxyphenyl)retinamide (4-MPR), the principal metabolite of 4-HPR, which are higher in elderly women with a high percentage of adipose tissue, are the major determinants of the retinol decrease. However, about 50% of the patients with altered dark-adaptometry are asymptomatic and the alterations are promptly reversible upon drug discontinuation. Since the combination of 4-HPR with the antiestrogen tamoxifen has shown a synergistic activity in the prevention of breast cancer in preclinical models, it is currently an important avenue of investigation in an attempt to reduce human breast cancer incidence and mortality. Moreover, a dose reduction of one or both agents in an effort to minimize toxicity while maintaining activity, would represent a major improvement in cancer chemoprevention. For these reasons, a randomized study of different dose combinations in Stage I-II breast cancer patients using a number of circulating growth factors as surrogate endpoints has been initiated. The main endpoint is the reduction of plasma IGF-I levels.
    Additional Material: 1 Ill.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1002/jcb.240531142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia (1995)
    New York, N.Y. : Wiley-Blackwell
    Journal of Cellular Biochemistry 59 (1995), S. 11-17 
    Details
    ISSN: 0730-2312
    Keywords: 4-HPR ; chemoprevention ; fenretinide ; Life and Medical Sciences ; Cell & Developmental Biology
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Biology , Chemistry and Pharmacology , Medicine
    Notes: We are conducting three randomized studies (breast cancer, basal cell carcinoma, oral leukoplakia) and report our methodological approach and accrual here.The aim of the breast cancer study is prevention of a contralateral primary lesion in women already treated for breast cancer; the aim of the basal cell carcinoma study is prevention of recurrences or new occurrence after surgical resection; and the aim of the oral leukoplakia study is prevention of recurrences and new occurrence after CO2 laser resection. The studies were planned according to a randomized design with an intervention arm vs a no-treatment arm. Patients in the intervention group receive 4-HPR at a dose of 200 mg po. The duration of treatment is five years in the breast cancer study, and one year in the basal cell carcinoma and oral leukoplakia studies. The breast cancer study started in March 1987, closing accrual on July 31, 1993. A total of 2,972 patients entered the study; 2,849 were evaluable (1,422 in the 4-HPR group and 1,427 in the control group). Of 2,849 evaluable patients, 867 completed the first five years, 1,142 are still ongoing, and 840 patients have interrupted the study for various reasons. Follow-up is ongoing. The basal cell carcinoma study started in January 1990. As of January 1994, a total of 786 patients had entered the study; 760 were evaluable (363 in the 4-HPR group and 367 in the control group). Of 760 patients in the study, 568 completed the first year, 62 are ongoing and 130 discontinued for various reasons. The study is ongoing. The oral leukoplakia study started in September 1988, closing accrual on February 1, 1994. A total of 174 patients entered the study; 170 were evaluable (84 in the 4-HPR group and 86 in the control group). The preliminary data of this study have been published. Updated results as of June 1994 were 11 recurrences and three new occurrences in the 4-HPR group; the control group also had 11 recurrences, as well as 12 new occurrences. Follow-up is ongoing.
    Additional Material: 3 Ill.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1002/jcb.240590803
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...